An expanded access study of 67Cu-SAR-bisPSMA for prostate cancer in USA
Latest Information Update: 01 Dec 2023
At a glance
- Drugs 67Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Expanded access; Therapeutic Use
- 01 Dec 2023 New trial record